<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
79378-220-30
</NDCCode>
<PackageDescription>
1 BOTTLE in 1 CARTON (79378-220-30) / 30 TABLET in 1 BOTTLE
</PackageDescription>
<NDC11Code>
79378-0220-30
</NDC11Code>
<ProductNDC>
79378-220
</ProductNDC>
<ProductTypeName>
HUMAN PRESCRIPTION DRUG
</ProductTypeName>
<ProprietaryName>
Livmarli
</ProprietaryName>
<ProprietaryNameSuffix/>
<NonProprietaryName>
Maralixibat Chloride
</NonProprietaryName>
<DosageFormName>
TABLET
</DosageFormName>
<RouteName>
ORAL
</RouteName>
<StartMarketingDate>
20250410
</StartMarketingDate>
<EndMarketingDate/>
<MarketingCategoryName>
NDA
</MarketingCategoryName>
<ApplicationNumber>
NDA219485
</ApplicationNumber>
<LabelerName>
Mirum Pharmaceuticals Inc.
</LabelerName>
<SubstanceName>
MARALIXIBAT CHLORIDE
</SubstanceName>
<StrengthNumber>
20
</StrengthNumber>
<StrengthUnit>
mg/1
</StrengthUnit>
<Pharm_Classes>
Ileal Bile Acid Transporter Inhibitor [EPC], Ileal Bile Acid Transporter Inhibitors [MoA], Organic Anion Transporting Polypeptide 2B1 Inhibitors [MoA]
</Pharm_Classes>
<DEASchedule/>
<Status>
Active
</Status>
<LastUpdate>
2025-04-25
</LastUpdate>
<PackageNdcExcludeFlag>
N
</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>
N
</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>
20261231
</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>
20250410
</StartMarketingDatePackage>
<EndMarketingDatePackage/>
<SamplePackage>
N
</SamplePackage>
</NDC>